Table 2 Univariate survival analysis.
Characteristic | Localized | Metastatic/Unresectable | ||||
|---|---|---|---|---|---|---|
Relapse-free survival | Overall survival | Overall survival | ||||
HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
Sex (male vs female) | 1.22 (0.96 to 1.56) | 0.105 | 1.09 (0.82 to 1.46) | 0.530 | 1.26 (0.95 to 1.68) | 0.0918 |
Age at diagnosis (>65 vs ≤65 years) | 1.32 (0.99 to 1.74) | 0.0387 | 1.70 (1.21 to 2.39) | 0.0005 | 1.39 (1.03 to 1.89) | 0.0175 |
Ethnicity (Chinese vs other) | 0.75 (0.55 to 1.04) | 0.0541 | 0.85 (0.58 to 1.24) | 0.372 | 0.92 (0.62 to 1.38) | 0.669 |
Cardiovascular co-morbidities (Present vs absent) | 1.24 (0.96 to 1.61) | 0.0841 | 1.41 (1.04 to 1.91) | 0.0179 | 1.17 (0.87 to 1.57) | 0.263 |
Tumor grade (3 vs 1–2) | 2.90 (2.27 to 3.70) | <0.0001 | 3.68 (2.76 to 4.91) | <0.0001 | 1.25 (0.91 to 1.73) | 0.172 |
Tumor size (>5 cm vs ≤5 cm) | 1.76 (1.34 to 2.30) | 0.0003 | 1.58 (1.14 to 2.18) | 0.0126 | — | — |
Tumor depth (deep vs superficial) | 1.16 (0.86 to 1.57) | 0.355 | 0.94 (0.65 to 1.36) | 0.729 | — | — |
Surgical margins (R1 vs R0) | 1.47 (1.13 to 1.91) | 0.0020 | 1.42 (1.04 to 1.93) | 0.0180 | — | — |
NLR at diagnosis (>2.5 vs ≤2.5) | 1.63 (1.28 to 2.07) | 0.0001 | 1.93 (1.45 to 2.57) | <0.0001 | 2.19 (1.62 to 2.97) | <0.0001 |
PLR at diagnosis (>182 vs ≤182) | 1.65 (1.29 to 2.10) | <0.0001 | 1.70 (1.28 to 2.26) | 0.0003 | 1.70 (1.28 to 2.26) | 0.0001 |
LMR at diagnosis (≤2.4 vs >2.4) | 1.71 (1.28 to 2.29) | <0.0001 | 1.85 (1.31 to 2.59) | <0.0001 | 2.04 (1.53 to 2.73) | <0.0001 |
Chemotherapy* (Yes vs No) | 1.08 (0.69 to 1.70) | 0.718 | 1.10 (0.65 to 1.87) | 0.714 | 0.67 (0.49 to 0.92) | 0.0067 |
Radiotherapy* (Yes vs No) | 0.84 (0.66 to 1.07) | 0.150 | 0.99 (0.74 to 1.32) | 0.956 | 0.91 (0.68 to 1.21) | 0.485 |
